TLR4 agonists as vaccine adjuvants: A chemist's perspective

Expert Review of Vaccines

Volumn 12, Issue 7, 2013, Pages 711-713

  Johnson, David A ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

AGP; aminoalkyl glucosaminide phosphate; lipid A mimetic; TLR4 agonist; TRIF selectivity; vaccine adjuvant

Indexed keywords

ALUMINUM POTASSIUM SULFATE; BACTERIUM LIPOPOLYSACCHARIDE; HEPATITIS B VACCINE; IMMUNOLOGICAL ADJUVANT; MYELOID DIFFERENTIATION FACTOR 88; PHOSPHORYL LIPID A; TOLL LIKE RECEPTOR 4 AGONIST; TOLL LIKE RECEPTOR AGONIST; UNCLASSIFIED DRUG; VACCINE; WART VIRUS VACCINE;

ADAPTIVE IMMUNITY; ADJUVANT THERAPY; BACTERIAL VIRULENCE; CD8+ T LYMPHOCYTE; CELL EXPANSION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SAFETY; EDITORIAL; ESCHERICHIA COLI; HUMAN; HUMORAL IMMUNITY; IMMUNOGENICITY; NANOEMULSION; PRIORITY JOURNAL; SYNTHESIS; T LYMPHOCYTE ACTIVATION; TH1 CELL;

ADJUVANTS, IMMUNOLOGIC; AIDS VACCINES; CANCER VACCINES; HUMANS; MALARIA VACCINES; TOLL-LIKE RECEPTOR 4; VACCINATION;

EID: 84880888220     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/14760584.2013.811189     Document Type: Editorial

References (23)

1. Becher JJ. Physica Subterranea (1667) quoted in Strathern P, Mendeleyev́;s Dream: The Quest for the Elements. Thomas Dunne Books, St. Martin's Press, NY, USA 206 (2000
2. McKee AS, Munks MW, Marrack P. How do adjuvants work? Important considerations for new generation adjuvants. Immunity 27(5), 687-690 (2007
3. Imoto M, Yoshimura H, Shimamoto T, Sakaguchi N, Kusumoto S, Shiba T. Total synthesis of Escherichia coli lipid A, the endotoxically active principle of cell-surface lipopolysaccharide. Bull. Chem. Soc. Jpn. 60(6), 2205-2214 (1987
4. Zughaier SM, Zimmer SM, Datta A, Carlson RW, Stephens DS. Differential induction of the Toll-like receptor 4-MyD88-dependent and -independent signaling pathways by endotoxins. Infect. Immun. 73(5), 2940-2950 (2005
5. Park BS, Song DH, Kim HM, Choi BS, Lee H, Lee JO. The structural basis of lipopolysaccharide recognition by the TLR4-MD-2 complex. Nature 458(7242), 1191-1195 (2009
6. Cluff CW. Monophosphoryl lipid A (MPL) as an adjuvant for anti-cancer vaccines: Clinical results. Adv. Exp. Med. Biol. 667, 111-123 (2009
7. Garçon N, Segal L, Tavares F, Van Mechelen M. The safety evaluation of adjuvants during vaccine development: The AS04 experience. Vaccine 29(27), 4453-4459 (2011
8. Mata-Haro V, Cekic C, Martin M, Chilton PM, Casella CR, Mitchell TC The vaccine adjuvant monophosphoryl lipid A as a TRIF-biased agonist of TLR4. Science 316(5831), 1628-1632 (2007
9. Fujimoto Y, Shimoyama A, Suda Y, Fukase K. Synthesis and immunomodulatory activities of Helicobacter pylori lipophilic terminus of lipopolysaccharide including lipid A. Carbohydr. Res. 356, 37-43 (2012
10. Johnson DA. Synthetic TLR4-Active glycolipids as vaccine adjuvants and standalone immunotherapeutics. Curr. Top. Med. Chem. 8(2), 64-79 (2008
11. Ishizaka ST, Hawkins LD. E6020: A synthetic Toll-like receptor 4 agonist as a vaccine adjuvant. Expert Rev. Vaccines 6(5), 773-784 (2007
12. Behzad H, Huckriede AL, Haynes L et al. GLA-SE, a synthetic Toll-like receptor 4 agonist, enhances T-cell responses to influenza vaccine in older adults. J. Infect. Dis. 205(3), 466-473 (2012
13. Arias MA, Van Roey GA, Tregoning JS et al. Glucopyranosyl Lipid Adjuvant (GLA), a Synthetic TLR4 agonist, promotes potent systemic and mucosal responses to intranasal immunization with HIVgp140. PLoS ONE 7(7), e41144 (2012
14. Fox CB, Friede M, Reed SG, Ireton GC. Synthetic and natural TLR4 agonists as safe and effective vaccine adjuvants. Subcell. Biochem. 53, 303-321 (2010
15. Singh M, Kazzaz J, Ugozzoli M et al. MF59 oil-in-water emulsion in combination with a synthetic TLR4 agonist (E6020) is a potent adjuvant for a combination Meningococcus vaccine. Hum. Vaccin. Immunother. 8(4), 486-490 (2012
16. Ouyang X, Negishi H, Takeda R, Fujita Y, Taniguchi T, Honda K. Cooperation between MyD88 and TRIF pathways in TLR synergy via IRF5 activation. Biochem. Biophys. Res. Commun. 354(4), 1045-1051 (2007
17. Johnson DA, Sowell CG, Johnson CL et al. Synthesis and biological evaluation of a new class of vaccine adjuvants: Aminoalkyl glucosaminide 4-phosphates (AGPs). Bioorg. Med. Chem. Lett. 9(15), 2273-2278 (1999
18. Bowen WS, Minns LA, Johnson DA, Mitchell TC, Hutton MM, Evans JT. Selective TRIF-dependent signaling by a synthetic Toll-like receptor 4 agonist. Sci. Signal. 5(211), ra13 (2012
19. Bazin HG, Murray TJ, Bowen WS et al. The 'Ethereal' nature of TLR4 agonism and antagonism in the AGP class of lipid A mimetics. Bioorg. Med. Chem. Lett. 18(20), 5350-5354 (2008
20. Roemer HR. The Safavid period. In: The Cambridge History of Iran (Volume 6). The Timurid and Safavid Periods. Jackson P, Lockhart L (Eds). Cambridge University Press, NY, USA 304-310 (1986
21. Duryee MJ, Willis MS, Freeman TL et al. Mechanisms of alcohol liver damage: Aldehydes, scavenger receptors, and autoimmunity. Front. Biosci. 9, 3145-3155 (2004
22. Schaffert CS, Duryee MJ, Hunter CD et al. Alcohol metabolites and lipopolysaccharide: Roles in the development and/or progression of alcoholic liver disease. World J. Gastroenterol. 15(10), 1209-1218 (2009
23. Duryee MJ, Klassen LW, Jones BL, Willis MS, Tuma DJ, Thiele GM. Increased immunogenicity to P815 cells modified with malondialdehyde and acetaldehyde. Int. Immunopharmacol. 8(8), 1112-1118 (2008 Diseases